GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (STU:3NK) » Definitions » Common Stock

Alphamab Oncology (STU:3NK) Common Stock : €0.00 Mil (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology Common Stock?

Alphamab Oncology's quarterly common stock stayed the same from Jun. 2023 (€0.00 Mil) to Dec. 2023 (€0.00 Mil) and stayed the same from Dec. 2023 (€0.00 Mil) to Jun. 2024 (€0.00 Mil).

Alphamab Oncology's annual common stock stayed the same from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.00 Mil) and stayed the same from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).


Alphamab Oncology Common Stock Historical Data

The historical data trend for Alphamab Oncology's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphamab Oncology Common Stock Chart

Alphamab Oncology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
Get a 7-Day Free Trial - - - - -

Alphamab Oncology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Alphamab Oncology Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Alphamab Oncology Business Description

Traded in Other Exchanges
Address
No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127
Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in the discovery, development manufacturing, and commercialization of biotherapeutics for cancer treatment. Its product pipeline includes various drug candidates such as KN035 (Envida), KN046, KN026, JSKN003, and KN019 among others in different stages of development.

Alphamab Oncology Headlines

No Headlines